Champions Story

CSBR -- USA Stock

USD 11.27 0.26 2.25%

Macroaxis Story

Champions Oncology Debt to Equity Ratio is relatively stable at the moment as compared to the past year. Champions Oncology reported last year Debt to Equity Ratio of 2.90. As of 09/14/2020, Free Cash Flow per Share is likely to grow to 0.06, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (1.1 M). While many traders today are more concerned about the preservation of capital over market returns, Champions Oncology could be one exception. Why are we still confident in hope for a quick recovery. Here I will also expose some primary fundamental factors affecting Champions Oncology's services, and outline how it will impact the outlook for investors this year.

Published over three months ago

View all stories for Champions Oncology | View All Stories

Is Champions Oncology about to turn this around?

Champions Oncology reported the previous year's revenue of 32.12 M. Net Loss for the year was (1.98 M) with profit before overhead, payroll, taxes, and interest of 15.24 M. About 21.0% of the company shares are held by company insiders. Champions Oncology has Price/Earnings (P/E) ratio of 605.0. The entity recorded a loss per share of 0.17. The firm had not issued any dividends in recent years. Champions Oncology had 1:12 split on the 12th of August 2015.

How important is Champions Oncology's Liquidity

Champions Oncology financial leverage refers to using borrowed capital as a funding source to finance Champions Oncology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Champions Oncology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Champions Oncology's total debt and its cash.

How Champions utilizes its cash?

To perform a cash flow analysis of Champions Oncology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Champions Oncology is receiving and how much cash it distributes out in a given period. The Champions Oncology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Champions Oncology Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Champions Oncology reported last year Net Cash Flow from Operations of 3.34 Million

What did Champions Oncology file with SEC?

The SEC filings are financial statements or other formal documents of Champions Oncology that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.

Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Champions shareholders may or may not be submitted as SEC does not always require it.

14th of December 2020

Financial Statements and Exhibits. Results of Operations and Financial Condition

View

21st of October 2020

Submission of Matters to a Vote of Security Holders

View

Going after Champions Financials

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Champions Oncology has an asset utilization ratio of 556.0 percent. This connotes that the company is making $5.56 for each dollar of assets. An increasing asset utilization means that Champions Oncology is more efficient with each dollar of assets it utilizes for everyday operations.

Our perspective of the latest Champions Oncology spike

Latest kurtosis is at 0.17. Champions Oncology exhibits very low volatility with skewness of -0.42 and kurtosis of 0.17. However, we advise investors to further study Champions Oncology technical indicators to make sure all market info is available and is reliable.

While some other companies in the biotechnology industry are either recovering or due for a correction, Champions Oncology may not be performing as strong as the other in terms of long-term growth potentials. In closing, as of the 14th of September 2020, we see that Champions Oncology follows the market closely. The enterprise is undervalued with low chance of distress within the next 24 months. Our current 30 days buy-hold-sell recommendation on the enterprise is Cautious Hold.

About Contributor

Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Champions Oncology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC